摘要
Transplant recipients usually have increased chances of graft rejection and graft vs host disease,requiring chronic immunosuppressive therapy.Nonetheless,longterm immunosuppression risks malignancies such as skin cancer,lymphoma,and Kaposi sarcoma.However,there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy.“Immunotherapy after liver transplantation:Where are we now?”is a study,where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients.The authors reported the graft rejection rates and the factors contributing to the rejection in the liver transplant recipients.
